

PROSTATE CANCER TESTING

Data-Driven Risk Stratification



1 in 8 Men are Affected by Prostate Cancer

Over 52,000 men in the UK are diagnosed with prostate cancer every year, with around 1 in 8 men affected in their lifetime.

Using a novel combination of biomarkers including PSA, our Prostate Cancer Risk Score can help to more accurately identify individuals at a higher risk of prostate cancer compared to a standalone PSA test. Those at lower risk are reassured and will not require unnecessary, invasive procedures.



Prostate Cancer Risk Score

Our Advanced Prostate Health blood test **combines a traditional PSA test with a novel Prostate Cancer Risk score** to more accurately assess your risk of prostate cancer.

PSA levels can be raised by many factors including urinary tract infection (UTI) and benign prostate hyperplasia. Almost 75% of men with a raised PSA who are referred for further investigations have a negative prostate biopsy.



Your Personalised Report

Our easy to interpret Advanced PSA test report will provide a **breakdown of your results**, what they mean and next steps.




Early Prostate Cancer May not Show Symptoms

Most men with early prostate cancer don't have any symptoms, however it's a good idea to get checked out just in case. Symptoms may be very similar to other conditions and can include;

- Difficulty emptying your bladder or a feeling your bladder hasn't emptied properly
- weak flow or difficulty starting to urinate
- needing to urinate more often especially during the night or a sudden need to urinate
- blood in the urine
- back/hip or pelvis pain

Data-Driven Risk Stratification

Recent studies by Randox have demonstrated that a novel serum combination of 4 biomarkers significantly improved the predicative potential of tPSA alone to identify patients with PCa.



Over **52,000** men in the UK are diagnosed with prostate cancer each year.

Almost **75%** of patients referred for investigation have a negative prostate biopsy (150,000 patients).

Prostate cancer costs for the NHS exceeded **£320.6 million** in 2020.

Biomarkers

EGF	IL-8	MCP-1	tPSA
-----	------	-------	------

Reference: McNally, C. J., et al (2022). A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into "Low-" and "High-Risk" Categories for Prostate Cancer. *Frontiers in oncology*, 12, 837127. <https://doi.org/10.3389/fonc.2022.837127>



66B Smith Street, Warwick Warwickshire, CV34 4HU
info@psatests.org.uk or info@myspsatests.org.uk

 @PSA_Tests  PSATests

CHARITY NUMBER 1109385

